| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW |
1 INSERM U567, Endocrinology, Metabolism and Cancer Department, Institut Cochin, Paris, France
2 CNRS UMR8104, Paris, France
3 Université Paris-Descartes, Site Cochin-Port-Royal, Paris, France
4 Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Oncogenetic Unit, Paris, France
5 Department of Experimental Medicine, University of l’Aquila, l’Aquila, Italy
6 Department of Endocrinology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Reference Center for Rare Adrenal Diseases, Paris, France
(Requests for offprints should be addressed to J Bertherat, Service des Maladies Endocriniennes et Métaboliques, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France; Email: jerome.bertherat{at}cch.aphp.fr)
Adrenocortical cancer (ACC) is a rare tumor with a poor prognosis. By contrast, benign adrenocortical tumors are frequent, underlying the importance of a correct diagnosis of malignancy of such tumors. ACC can be diagnosed by the investigation of endocrine signs of steroid excess, symptoms due to tumor growth or an adrenal incidentaloma. Hormonal investigations demonstrate in most ACC steroid oversecretion, the dominant characteristics being a co-secretion of cortisol and androgens. Imaging by CT-scan or MRI shows a large heterogeneous tumor with a low fat content. Careful pathological investigation with the assessment of the Weiss score is important for the diagnosis of malignancy. Molecular markers can also be helpful and in the future might be important for prognosis. Tumors localized to the adrenal gland (McFarlane stages 1 and 2) have a better outcome than invasive and metastatic tumors (stages 3 and 4). Tumor removal by a specialized team is crucial for treatment and should always aim at complete removal. In patients with metastatic or progressive disease, medical treatment is started with mitotane that requires a close monitoring of its blood level. Surgery is indicated when possible for local recurrence but also in some cases of metastasis. Local treatment (radiofrequency, chemoembolization, and radiation therapy) can have some indications for metastatic disease. In patients with disease progression cytotoxic chemotherapy can be used. Despite the best care, the overall prognosis of ACC is poor with a 5-year survival rate below 30% in most series. Therefore, progress in the understanding of the pathophysiology of ACC is important. Despite the rarity of ACC, significant advances have been made in the understanding of its pathogenesis the last decade. These progresses came mainly from the study of the genetics of ACC, both at the germline level in rare familial diseases, and at the somatic level by the study of molecular alterations in sporadic tumors. These advances underline the importance of genetic alterations in ACC development and point-out to various chromosomal regions (2, 11p15, 11q, 17p13) and genes (IGF-II, p53, ß-catenin, ACTH receptor). This review will summarize these advances as well as the current clinical management of ACC.
This article has been cited by other articles:
|
|
 |
|
  M. C. Zatelli, E. Gentilin, F. Daffara, F. Tagliati, G. Reimondo, G. Carandina, M. R. Ambrosio, M. Terzolo, and E. C. degli Uberti Therapeutic Concentrations of Mitotane (o,p'-DDD) Inhibit Thyrotroph Cell Viability and TSH Expression and Secretion in a Mouse Cell Line Model Endocrinology, June 1, 2010; 151(6): 2453 - 2461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 M. Doghman, A. E. Wakil, B. Cardinaud, E. Thomas, J. Wang, W. Zhao, M. H. C. Peralta-Del Valle, B. C. Figueiredo, G. P. Zambetti, and E. Lalli Regulation of Insulin-like Growth Factor-Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors Cancer Res., June 1, 2010; 70(11): 4666 - 4675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Wangberg, A Khorram-Manesh, S Jansson, B Nilsson, O Nilsson, C E Jakobsson, S Lindstedt, A Oden, and H Ahlman The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane Endocr. Relat. Cancer, February 18, 2010; 17(1): 265 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 S. Wortmann, M. Quinkler, C. Ritter, M. Kroiss, S. Johanssen, S. Hahner, B. Allolio, and M. Fassnacht Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma Eur. J. Endocrinol., February 1, 2010; 162(2): 349 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L Ronchi, S. Sbiera, L. Kraus, S. Wortmann, S. Johanssen, P. Adam, H. S Willenberg, S. Hahner, B. Allolio, and M. Fassnacht Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy Endocr. Relat. Cancer, September 1, 2009; 16(3): 907 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Fenske, H.-U. Volker, P. Adam, S. Hahner, S. Johanssen, S. Wortmann, M. Schmidt, M. Morcos, H.-K. Muller-Hermelink, B. Allolio, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma Endocr. Relat. Cancer, September 1, 2009; 16(3): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Tombol, P. M Szabo, V. Molnar, Z. Wiener, G. Tolgyesi, J. Horanyi, P. Riesz, P. Reismann, A. Patocs, I. Liko, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis Endocr. Relat. Cancer, September 1, 2009; 16(3): 895 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 A. C. Kim, F. M. Barlaskar, J. H. Heaton, T. Else, V. R. Kelly, K. T. Krill, J. O. Scheys, D. P. Simon, A. Trovato, W.-H. Yang, et al. In Search of Adrenocortical Stem and Progenitor Cells Endocr. Rev., May 1, 2009; 30(3): 241 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bielinska, H. Parviainen, S. Kiiveri, M. Heikinheimo, and D. B. Wilson Review Paper: Origin and Molecular Pathology of Adrenocortical Neoplasms Veterinary Pathology, March 1, 2009; 46(2): 194 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 A. de Reynies, G. Assie, D. S. Rickman, F. Tissier, L. Groussin, F. Rene-Corail, B. Dousset, X. Bertagna, E. Clauser, and J. Bertherat Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival J. Clin. Oncol., March 1, 2009; 27(7): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 T. J. Giordano, R. Kuick, T. Else, P. G. Gauger, M. Vinco, J. Bauersfeld, D. Sanders, D. G. Thomas, G. Doherty, and G. Hammer Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling Clin. Cancer Res., January 15, 2009; 15(2): 668 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Daffara, S. De Francia, G. Reimondo, B. Zaggia, E. Aroasio, F. Porpiglia, M. Volante, A. Termine, F. Di Carlo, L. Dogliotti, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly Endocr. Relat. Cancer, December 1, 2008; 15(4): 1043 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 K. Hemminki, X. Shu, X. Li, J. Ji, J. Sundquist, and K. Sundquist Familial Risks for Hospitalization with Endocrine Diseases J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4755 - 4758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B d'Alva, G. Abiven-Lepage, V. Viallon, L. Groussin, M. A. Dugue, X. Bertagna, and J. Bertherat Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess Eur. J. Endocrinol., November 1, 2008; 159(5): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gaujoux, F. Tissier, L. Groussin, R. Libe, B. Ragazzon, P. Launay, A. Audebourg, B. Dousset, X. Bertagna, and J. Bertherat Wnt/{beta}-Catenin and 3',5'-Cyclic Adenosine 5'-Monophosphate/Protein Kinase A Signaling Pathways Alterations and Somatic {beta}-Catenin Gene Mutations in the Progression of Adrenocortical Tumors J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4135 - 4140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 M. Rizk-Rabin, G. Assie, F. Rene-Corail, K. Perlemoine, H. Hamzaoui, F. Tissier, M. Lieberherr, X. Bertagna, J. Bertherat, and Z. Bouizar Differential Expression of Parathyroid Hormone-Related Protein in Adrenocortical Tumors: Autocrine/Paracrine Effects on the Growth and Signaling Pathways in H295R Cells Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2275 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Libe, A. Fratticci, J. Coste, F. Tissier, A. Horvath, B. Ragazzon, F. Rene-Corail, L. Groussin, X. Bertagna, M. L. Raffin-Sanson, et al. Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors Clin. Cancer Res., June 15, 2008; 14(12): 4016 - 4024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Vincent-Dejean, L Cazabat, L Groussin, K Perlemoine, G Fumey, F Tissier, X Bertagna, and J Bertherat Identification of a clinically homogenous subgroup of benign cortisol-secreting adrenocortical tumors characterized by alterations of the protein kinase A (PKA) subunits and high PKA activity. Eur. J. Endocrinol., June 1, 2008; 158(6): 829 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
 J. Bertherat, J. Coste, X. Bertagna, G. Dickstein, C. Shechner, O. Nativ, J. E. Lee, A. Machens, H. Dralle, M. Terzolo, et al. Adjuvant Mitotane in Adrenocortical Carcinoma N. Engl. J. Med., September 20, 2007; 357(12): 1256 - 1259. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
